On January 25th, British American Tobacco announced in a statement that its subsidiary, Reynolds American Inc. (Reynolds), will appeal the marketing ban by the U.S. Food and Drug Administration on its Vuse Vibe Tank menthol 3.0% and Vuse Ciro Cartridge menthol 1.5%.
On January 24th, the FDA rejected marketing applications for two menthol additives used in the Vuse Vibe and Vuse Ciro e-cigarettes, which are sold in the United States by Reynolds, a subsidiary of BAT.
The company stated, "Reynolds intends to immediately seek a suspension of enforcement and will pursue other appropriate avenues to continue providing innovative products to adult nicotine consumers over the age of 21 without interruption.
We still have full confidence in the quality of all Reynolds products, and we believe that the FDA has sufficient evidence to determine whether the marketing of these products is appropriate to protect public health.
Anti-smoking activists have contested claims that mint-flavored e-cigarettes are not attractive to underage consumers. The chair of the Campaign for Tobacco-Free Kids, Matthew Myers, responded with a statement saying, "Existing evidence shows that non-tobacco flavored e-cigarettes, including mint-flavored e-cigarettes, pose known substantial risks in terms of attractiveness, uptake, and use among young people. In contrast, data shows that tobacco-flavored e-cigarettes have a different level of appeal among young people and, therefore, do not pose an equal level of risk.
Morgan Stanley has stated that it expects the rejected products during BAT's appeal to remain on the US market with minimal impact on the company's operations. The bank wrote in an investor note that "in the long-term, if this refusal reflects broader efforts by the FDA to ban menthol e-cigarettes, BAT's US cigarette business may benefit from its menthol blend as it could deter some smokers from quitting or switching to lower-risk products." According to Morgan Stanley, Reynolds' Newport brand accounts for around 40% of BAT's US cigarette sales.
On January 24, the FDA’s refusal to approve Vuse’s additional flavor highlight its longstanding resistance to approve menthol-flavored e-cigarettes. So far, the agency has only approved tobacco-flavored e-cigarettes.
The FDA has designated the pre-market tobacco product application and modified risk tobacco product application to IQOS' updated menthol product. This could ultimately make FiMo International's heat-not-burn product one of the few on the market as a menthol reduced-risk alternative.
FDA Issues Marketing Denial Orders for Two Vuse Products
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
